STAAR Surgical (NASDAQ:STAA) Given Hold Rating at Needham & Company LLC

STAAR Surgical (NASDAQ:STAA)‘s stock had its “hold” rating reissued by stock analysts at Needham & Company LLC in a report released on Wednesday,Benzinga reports.

STAA has been the subject of several other research reports. Mizuho lowered STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $45.00 to $17.00 in a research report on Wednesday. Stephens raised shares of STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Canaccord Genuity Group reduced their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research report on Monday, December 9th. Finally, BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and a consensus target price of $36.50.

STAAR Surgical Trading Down 3.2 %

STAA opened at $21.88 on Wednesday. The firm has a market cap of $1.08 billion, a P/E ratio of 49.73 and a beta of 0.62. STAAR Surgical has a 12 month low of $21.13 and a 12 month high of $52.68. The stock has a 50-day moving average of $23.94 and a 200 day moving average of $29.33.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $24.33 per share, with a total value of $559,590.00. Following the completion of the acquisition, the insider now owns 10,848,631 shares in the company, valued at $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 105,876 shares of company stock valued at $2,487,168 in the last ninety days. Company insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd raised its position in shares of STAAR Surgical by 41.0% during the 4th quarter. WINTON GROUP Ltd now owns 42,964 shares of the medical instruments supplier’s stock worth $1,044,000 after purchasing an additional 12,496 shares during the last quarter. Vanguard Group Inc. raised its position in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares during the last quarter. LPL Financial LLC raised its position in shares of STAAR Surgical by 45.3% during the 4th quarter. LPL Financial LLC now owns 15,994 shares of the medical instruments supplier’s stock worth $388,000 after purchasing an additional 4,989 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical during the 4th quarter worth about $180,000. Finally, American Century Companies Inc. raised its position in shares of STAAR Surgical by 70.0% during the 4th quarter. American Century Companies Inc. now owns 13,256 shares of the medical instruments supplier’s stock worth $322,000 after purchasing an additional 5,457 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.